300841 康华生物
已收盘 09-09 15:00:00
资讯
新帖
简况
股市必读：9月7日康华生物现1笔折价17.98%的大宗交易 合计成交1024.59万元
证券之星 · 09-08 01:03
股市必读：9月7日康华生物现1笔折价17.98%的大宗交易 合计成交1024.59万元
康华生物：纳美信生物的递送系统平台包括新型可电离阳离子脂质分子、LNP处方优化、LNP-mRNA冻干制剂工艺等
证券之星 · 08-25
康华生物：纳美信生物的递送系统平台包括新型可电离阳离子脂质分子、LNP处方优化、LNP-mRNA冻干制剂工艺等
康华生物：冻干呼吸道合胞病毒mRNA疫苗于2026年5月启动Ⅱ期临床试验
证券之星 · 08-25
康华生物：冻干呼吸道合胞病毒mRNA疫苗于2026年5月启动Ⅱ期临床试验
康华生物：公司将在收到并确认信息之后提供最近一期股东户数数据
证券之星 · 08-25
康华生物：公司将在收到并确认信息之后提供最近一期股东户数数据
股市必读：康华生物中报 - 第二季度单季净利润同比增长21.29%
证券之星 · 08-19
股市必读：康华生物中报 - 第二季度单季净利润同比增长21.29%
图解康华生物中报：第二季度单季净利润同比增长21.29%
证券之星 · 08-18
图解康华生物中报：第二季度单季净利润同比增长21.29%
康华生物（300841）披露2026年半年度报告，8月17日股价下跌0.27%
证券之星 · 08-17
康华生物（300841）披露2026年半年度报告，8月17日股价下跌0.27%
股市必读：康华生物新发布《关于对外投资暨关联交易的进展公告》
证券之星 · 08-04
股市必读：康华生物新发布《关于对外投资暨关联交易的进展公告》
康华生物（300841）披露2026年第二次临时股东会决议公告，7月21日股价下跌2.31%
证券之星 · 07-21
康华生物（300841）披露2026年第二次临时股东会决议公告，7月21日股价下跌2.31%
股市必读：康华生物（300841）7月7日董秘有最新回复
证券之星 · 07-08
股市必读：康华生物（300841）7月7日董秘有最新回复
康华生物：目前公司不涉及补税事项
证券之星 · 07-07
康华生物：目前公司不涉及补税事项
康华生物最新公告：拟出资3.6亿元参与设立生物医药产业投资基金
证券之星 · 07-01
康华生物最新公告：拟出资3.6亿元参与设立生物医药产业投资基金
康华生物：2026年一季度净利润同比增长32.14%
证券之星 · 06-11
康华生物：2026年一季度净利润同比增长32.14%
康华生物（300841）披露纳美信RSV疫苗启动Ⅱ期临床试验公告，6月01日股价上涨0.65%
证券之星 · 06-01
康华生物（300841）披露纳美信RSV疫苗启动Ⅱ期临床试验公告，6月01日股价上涨0.65%
康华生物(300841.SZ)：纳美信冻干呼吸道合胞病毒mRNA疫苗启动Ⅱ期临床试验
智通财经 · 05-29
康华生物(300841.SZ)：纳美信冻干呼吸道合胞病毒mRNA疫苗启动Ⅱ期临床试验
股市必读：康华生物（300841）今年截至5月27日累计跌幅已超30%
证券之星 · 05-28
股市必读：康华生物（300841）今年截至5月27日累计跌幅已超30%
康华生物：持续聚焦主营业务经营，扎实做好研发创新、生产运营与内部治理
证券之星 · 05-20
康华生物：持续聚焦主营业务经营，扎实做好研发创新、生产运营与内部治理
康华生物：重组六价诺如病毒疫苗可覆盖全球约90%以上诺如病毒流行毒株
证券之星 · 05-20
康华生物：重组六价诺如病毒疫苗可覆盖全球约90%以上诺如病毒流行毒株
康华生物：2026年一季度实现营业收入17,245.18万元，同比增长25.02%
证券之星 · 05-18
康华生物：2026年一季度实现营业收入17,245.18万元，同比增长25.02%
5月14日康华生物现4544.58万元大宗交易
证券之星 · 05-14
5月14日康华生物现4544.58万元大宗交易
加载更多
公司概况
公司名称：
成都康华生物制品股份有限公司
所属行业：
医药制造业
上市日期：
2020-06-16
主营业务：
成都康华生物制品股份有限公司的主营业务是生物制品的研发、生产与销售。公司的主要产品是冻干人用狂犬病疫苗（人二倍体细胞）、ACYW135群脑膜炎球菌多糖疫苗。
发行价格：
70.37
{"stockData":{"symbol":"300841","market":"SZ","secType":"STK","nameCN":"康华生物","latestPrice":50.5,"timestamp":1788937407000,"preClose":51.54,"halted":0,"volume":2802874,"delay":0,"changeRate":-0.0202,"floatShares":122000000,"shares":130000000,"eps":1.8972,"marketStatus":"已收盘","change":-1.04,"latestTime":"09-09 15:00:00","open":51.16,"high":51.19,"low":50.18,"amount":142000000,"amplitude":0.0196,"askPrice":50.51,"askSize":2,"bidPrice":50.5,"bidSize":69,"shortable":0,"etf":0,"ttmEps":1.8972,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1789003800000},"marketStatusCode":5,"adr":0,"adjPreClose":51.54,"symbolType":"stock","openAndCloseTimeList":[[1788917400000,1788924600000],[1788930000000,1788937200000]],"highLimit":56.69,"lowLimit":46.39,"ibTradeSell":false,"ibTradeBuySell":false,"totalEquity":129946899,"isCdr":false,"pbRate":1.85,"roa":"--","peRate":26.618174,"roe":"3.92%","epsLYR":1.6922,"committee":0.139241,"marketValue":6562000000,"turnoverRate":0.0231,"status":1,"floatMarketCap":6140000000},"requestUrl":"/m/hq/s/300841","defaultTab":"news","newsList":[{"id":"2665310374","title":"股市必读：9月7日康华生物现1笔折价17.98%的大宗交易 合计成交1024.59万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665310374","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665310374?lang=zh_cn&edition=full","pubTime":"2026-09-08 01:03","pubTimestamp":1788800591,"startTime":"0","endTime":"0","summary":"截至2026年9月7日收盘，康华生物报收于50.99元，上涨0.1%，换手率1.99%，成交量2.42万手，成交额1.24亿元。当日关注点交易信息汇总：9月7日康华生物主力资金净流入36.89万元，游资资金净流入432.74万元，散户资金净流出469.63万元。大宗交易9月7日康华生物现1笔折价17.98%的大宗交易，合计成交1024.59万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090800000563.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662378330","title":"康华生物：纳美信生物的递送系统平台包括新型可电离阳离子脂质分子、LNP处方优化、LNP-mRNA冻干制剂工艺等","url":"https://stock-news.laohu8.com/highlight/detail?id=2662378330","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662378330?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:38","pubTimestamp":1787629099,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物(300841)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司在mRNA的LNP的递送技术上有哪些突破？康华生物回复：尊敬的投资者您好！公司通过对纳美信生物的投资深化mRNA全链条技术平台的建设，纳美信生物的递送系统平台包括：新型可电离阳离子脂质分子、LNP处方优化、LNP-mRNA冻干制剂工艺等；持续推动靶向递送、tLNP（抗体偶联）等前沿领域研发工作并取得突破，部分成果已申请专利。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：陈思雨","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500021922.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662352783","title":"康华生物：冻干呼吸道合胞病毒mRNA疫苗于2026年5月启动Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2662352783","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662352783?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:38","pubTimestamp":1787629099,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物(300841)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问公司RSV mRNA疫苗临床进展如何？康华生物回复：尊敬的投资者您好！冻干呼吸道合胞病毒mRNA疫苗于2026年5月启动Ⅱ期临床试验，6月完成全部375例试验参与者入组接种。公司将按照信息披露相关规定对研发进展进行披露，敬请关注公司后续相关公告。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500021921.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662783310","title":"康华生物：公司将在收到并确认信息之后提供最近一期股东户数数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2662783310","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662783310?lang=zh_cn&edition=full","pubTime":"2026-08-25 11:38","pubTimestamp":1787629098,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物(300841)08月24日在投资者关系平台上答复投资者关心的问题。投资者提问：请问把带有时间和姓名的股票交易软件持仓截图和身份证一并扫描发送至公司邮箱，可以获知 非定期报告相关时点的股东人数吗？盼你们具体，明确答复。顺祝健康，快乐 【比如截至到2026年8月20日贵公司的股东人数是多少?康华生物回复：尊敬的投资者您好！您可将本人持股证明及身份证件等证明文件发送至公司对外披露邮箱：contact@kangh.com，公司将在收到并确认信息之后提供最近一期股东户数数据。谢谢！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：沈彬","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082500021919.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660999934","title":"股市必读：康华生物中报 - 第二季度单季净利润同比增长21.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660999934","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660999934?lang=zh_cn&edition=full","pubTime":"2026-08-19 01:23","pubTimestamp":1787073836,"startTime":"0","endTime":"0","summary":"截至2026年8月18日收盘，康华生物报收于54.22元，上涨11.31%，换手率9.09%，成交量11.05万手，成交额5.91亿元。股本股东变化：截至2026年6月30日股东户数为1.79万户，较3月31日增加5.68%。业绩披露要点：2026年上半年归母净利润1.41亿元，同比上升23.25%。第二季度单季度主营收入3.66亿元，同比上升5.76%；单季度归母净利润1.14亿元，同比上升21.29%；单季度扣非净利润1.09亿元，同比上升19.09%；负债率8.99%，投资收益251.88万元，财务费用-155.47万元，毛利率89.76%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081900001405.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660439075","title":"图解康华生物中报：第二季度单季净利润同比增长21.29%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660439075","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660439075?lang=zh_cn&edition=full","pubTime":"2026-08-18 01:18","pubTimestamp":1786987085,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物2026年中报显示，上半年度公司主营收入5.38亿元，同比上升11.25%；归母净利润1.41亿元，同比上升23.25%；扣非净利润1.34亿元，同比上升20.28%；其中2026年第二季度，公司单季度主营收入3.66亿元，同比上升5.76%；单季度归母净利润1.14亿元，同比上升21.29%；单季度扣非净利润1.09亿元，同比上升19.09%；负债率8.99%，投资收益251.88万元，财务费用-155.47万元，毛利率89.76%。财报数据概要请见下图:本文数据来源于康华生物2026年中报，仅供参考不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081800001566.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2660433050","title":"康华生物（300841）披露2026年半年度报告，8月17日股价下跌0.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2660433050","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2660433050?lang=zh_cn&edition=full","pubTime":"2026-08-17 22:19","pubTimestamp":1786976364,"startTime":"0","endTime":"0","summary":"截至2026年8月17日收盘，康华生物报收于48.71元，较前一交易日下跌0.27%，最新总市值为63.3亿元。该股当日开盘48.72元，最高48.92元，最低47.13元，成交额达1.2亿元，换手率为2.09%。近日，康华生物披露《2026年半年度报告》。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081700035343.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2656305604","title":"股市必读：康华生物新发布《关于对外投资暨关联交易的进展公告》","url":"https://stock-news.laohu8.com/highlight/detail?id=2656305604","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2656305604?lang=zh_cn&edition=full","pubTime":"2026-08-04 01:40","pubTimestamp":1785778823,"startTime":"0","endTime":"0","summary":"截至2026年8月3日收盘，康华生物报收于46.19元，下跌0.13%，换手率1.47%，成交量1.74万手，成交额8046.41万元。公司公告汇总关于对外投资暨关联交易的进展公告成都康华生物制品股份有限公司与纳美信（上海）生物科技有限公司及其现有股东签署投资协议，拟通过认购新增注册资本及受让股权方式最终持有纳美信100%股权。纳美信已于近日完成第一期交易的工商变更登记，并取得新的营业执照。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026080400001367.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2653754482","title":"康华生物（300841）披露2026年第二次临时股东会决议公告，7月21日股价下跌2.31%","url":"https://stock-news.laohu8.com/highlight/detail?id=2653754482","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2653754482?lang=zh_cn&edition=full","pubTime":"2026-07-21 18:03","pubTimestamp":1784628186,"startTime":"0","endTime":"0","summary":"截至2026年7月21日收盘，康华生物报收于44.89元，较前一交易日下跌2.31%，最新总市值为58.33亿元。公司于近日披露《2026年第二次临时股东会决议公告》。公告显示，成都康华生物制品股份有限公司于2026年7月20日召开2026年第二次临时股东会，会议采用现场与网络投票相结合方式召开，无否决议案。出席会议的股东共140人，代表有表决权股份10,785,849股，占公司总股本的8.3002%，全部通过网络投票参与。同意票占出席会议有表决权股份的93.4332%，中小股东同意比例为72.7871%。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026072100033745.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649932370","title":"股市必读：康华生物（300841）7月7日董秘有最新回复","url":"https://stock-news.laohu8.com/highlight/detail?id=2649932370","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649932370?lang=zh_cn&edition=full","pubTime":"2026-07-08 02:47","pubTimestamp":1783450029,"startTime":"0","endTime":"0","summary":"截至2026年7月7日收盘，康华生物报收于46.39元，下跌4.27%，换手率1.76%，成交量2.09万手，成交额9824.68万元。董秘最新回复投资者： 董秘你好，最近有很多生物医药公司公告需要补税，请问康华是否需要补税？目前公司不涉及补税事项。交易信息汇总资金流向7月7日主力资金净流出363.16万元，占总成交额0.0%；游资资金净流出384.94万元，占总成交额0.0%；散户资金净流入748.11万元，占总成交额0.0%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070800001431.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649600840","title":"康华生物：目前公司不涉及补税事项","url":"https://stock-news.laohu8.com/highlight/detail?id=2649600840","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2649600840?lang=zh_cn&edition=full","pubTime":"2026-07-07 16:00","pubTimestamp":1783411234,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物(300841)07月07日在投资者关系平台上答复投资者关心的问题。投资者提问：董秘你好，最近有很多生物医药公司公告需要补税，请问康华是否需要补税？谢谢康华生物回复：尊敬的投资者，您好！目前公司不涉及补税事项。感谢您的关注！本文数据来源于深圳证券交易所互动易，仅供参考不构成投资建议。责任编辑：刘浩然","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070700024706.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2648517183","title":"康华生物最新公告：拟出资3.6亿元参与设立生物医药产业投资基金","url":"https://stock-news.laohu8.com/highlight/detail?id=2648517183","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2648517183?lang=zh_cn&edition=full","pubTime":"2026-07-01 19:09","pubTimestamp":1782904176,"startTime":"0","endTime":"0","summary":"康华生物(300841.SZ)公告称，公司拟与四川创新发展投资管理有限公司、四川省先进制造投资引导基金合伙企业(有限合伙)、四川产业振兴基金投资集团有限公司或其指定主体、上海上实生物医药管理咨询有限公司共同出资设立四川振兴生物医药产业投资基金合伙企业(有限合伙)。该基金首期认缴出资总额为12亿元，公司作为有限合伙人拟以自有资金认缴出资3.6亿元，占出资总额的30%。本次交易构成关联交易，尚需获得公司股东会批准。以上内容为证券之星据公开信息整理，仅供参考不构成投资建议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026070100036918.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","161726","BK0239","399441"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642403911","title":"康华生物：2026年一季度净利润同比增长32.14%","url":"https://stock-news.laohu8.com/highlight/detail?id=2642403911","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2642403911?lang=zh_cn&edition=full","pubTime":"2026-06-11 11:33","pubTimestamp":1781148789,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物06月10日在投资者关系平台上答复投资者关心的问题。公司2026年一季度实现营业收入17,245.18万元，同比增长25.02%；归属于上市公司股东的净利润2,736.34万元，同比增长32.14%，经营活动现金净流量同比转正，彰显了公司的业绩韧性与抗风险能力。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026061100014721.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640930049","title":"康华生物（300841）披露纳美信RSV疫苗启动Ⅱ期临床试验公告，6月01日股价上涨0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2640930049","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2640930049?lang=zh_cn&edition=full","pubTime":"2026-06-01 17:56","pubTimestamp":1780307816,"startTime":"0","endTime":"0","summary":"截至2026年6月1日收盘，康华生物报收于48.05元，较前一交易日上涨0.65%，最新总市值为62.44亿元。近日，康华生物披露《关于纳美信（上海）生物科技有限公司RSV疫苗启动Ⅱ期临床试验的自愿性信息披露公告》。公告显示，公司拟收购的纳美信（上海）生物科技有限公司自主研发的冻干呼吸道合胞病毒mRNA疫苗已正式启动Ⅱ期临床试验。目前公司对纳美信的投资事项处于第一期交易交割准备阶段，尚未取得控制权。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026060100028172.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2639210706","title":"康华生物(300841.SZ)：纳美信冻干呼吸道合胞病毒mRNA疫苗启动Ⅱ期临床试验","url":"https://stock-news.laohu8.com/highlight/detail?id=2639210706","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2639210706?lang=zh_cn&edition=full","pubTime":"2026-05-29 19:04","pubTimestamp":1780052677,"startTime":"0","endTime":"0","summary":"智通财经APP讯， 康华生物 发布公告，近日，公司拟收购的纳美信(上海)生物科技有限公司自主研发的冻干呼吸道合胞病毒mRNA疫苗，已正式启动Ⅱ期临床试验。RSV疫苗适用于预防呼吸道合胞病毒感染引起的下呼吸道疾病。目前全球范围内有3款呼吸道合胞病毒疫苗产品获批上市，国内尚无呼吸道合胞病毒疫苗获批上市。RSV疫苗采用冻干mRNA疫苗工艺，预期可在2℃-8℃稳定存储。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1447898.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"康华生物(300841.SZ)：纳美信冻干呼吸道合胞病毒mRNA疫苗启动Ⅱ期临床试验","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159646","BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638067687","title":"股市必读：康华生物（300841）今年截至5月27日累计跌幅已超30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2638067687","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2638067687?lang=zh_cn&edition=full","pubTime":"2026-05-28 01:37","pubTimestamp":1779903428,"startTime":"0","endTime":"0","summary":"截至2026年5月27日收盘，康华生物报收于47.41元，下跌4.01%，换手率3.11%，成交量3.69万手，成交额1.77亿元。交易信息汇总股价提醒5月27日康华生物收盘报47.41元，跌4.01%，当日成交369.38万元。该股已连续8日下跌，当年累计跌幅30.62%。前10个交易日中，主力资金累计净流出1.09亿元，股价累计下跌13.09%；融资余额累计增加713.16万元，融券余量累计增加1.46万股。资金流向5月27日主力资金净流出1785.8万元；游资资金净流入1465.57万元；散户资金净流入320.23万元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052800001146.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636847968","title":"康华生物：持续聚焦主营业务经营，扎实做好研发创新、生产运营与内部治理","url":"https://stock-news.laohu8.com/highlight/detail?id=2636847968","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636847968?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:52","pubTimestamp":1779281550,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物05月19日在投资者关系平台上答复投资者关心的问题。投资者提问：康华股价连跌这么多年，今年连跌5个月，请问康华生物公司怎么进行市值管理？此外，公司已先后实施两次股份回购并完成注销，累计注销金额3.23亿元，切实以实际行动回馈广大股东；三是持续完善公司治理结构，严格依规履行信息披露义务，并通过业绩说明会、投资者互动平台等多渠道保持常态化沟通，增进市场对公司经营与价值的认知与认同。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041283.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636284765","title":"康华生物：重组六价诺如病毒疫苗可覆盖全球约90%以上诺如病毒流行毒株","url":"https://stock-news.laohu8.com/highlight/detail?id=2636284765","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636284765?lang=zh_cn&edition=full","pubTime":"2026-05-20 20:52","pubTimestamp":1779281550,"startTime":"0","endTime":"0","summary":"康华生物回复：尊敬的投资者您好，公司重组六价诺如病毒疫苗针对全球主流流行毒株GI.1、GII.2、GII.3、GII.4、GII.6、GII.17进行研发设计，结合全球及国内近年诺如病毒流行病学监测数据，该产品理论上可覆盖全球约90%以上诺如病毒流行毒株，目前该产品正处于临床试验阶段，若有实质性和阶段性进展公司会及时披露。重组六价诺如病毒疫苗是公司重点布局的创新疫苗管线，公司将根据其研发进展合理进行资源投入，全力加快研发进程，稳步推进项目落地。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026052000041288.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239","159646"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2636047799","title":"康华生物：2026年一季度实现营业收入17,245.18万元，同比增长25.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=2636047799","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2636047799?lang=zh_cn&edition=full","pubTime":"2026-05-18 15:07","pubTimestamp":1779088036,"startTime":"0","endTime":"0","summary":"证券之星消息，康华生物05月18日在投资者关系平台上答复投资者关心的问题。公司2026年一季度实现营业收入17,245.18万元，同比增长25.02%；归属于上市公司股东的净利润2,736.34万元，同比增长32.14%，经营活动现金净流量同比转正，彰显了公司的业绩韧性与抗风险能力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051800015583.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635790194","title":"5月14日康华生物现4544.58万元大宗交易","url":"https://stock-news.laohu8.com/highlight/detail?id=2635790194","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2635790194?lang=zh_cn&edition=full","pubTime":"2026-05-14 17:27","pubTimestamp":1778750838,"startTime":"0","endTime":"0","summary":"证券之星消息，5月14日康华生物发生大宗交易，交易数据如下：大宗交易成交价格54.82元，相对当日收盘价折价1.6%，成交82.9万股，成交金额4544.58万元，买方营业部为中国银河证券股份有限公司上海共康路证券营业部，卖方营业部为中国中金财富证券有限公司上海黄浦区中山东二路证券营业部。截至2026年5月14日收盘，康华生物报收于55.71元，下跌3.45%，换手率1.75%，成交量2.08万手，成交额1.17亿元。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026051400030269.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["300841","BK0239"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1788948550869,"stockEarnings":[{"period":"1week","weight":-0.0228},{"period":"1month","weight":0.0673},{"period":"3month","weight":0.1469},{"period":"6month","weight":-0.1719},{"period":"1year","weight":-0.3181},{"period":"ytd","weight":-0.2792}],"compareEarnings":[{"period":"1week","weight":-0.0099},{"period":"1month","weight":0.0001},{"period":"3month","weight":-0.0132},{"period":"6month","weight":-0.0457},{"period":"1year","weight":0.0297},{"period":"ytd","weight":-0.0071}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"成都康华生物制品股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"17937人(较上一季度增加5.68%)","perCapita":"6777股","listingDate":"2020-06-16","address":"四川省成都市龙泉驿区经济技术开发区北京路182号","registeredCapital":"12994万元","survey":" 成都康华生物制品股份有限公司的主营业务是生物制品的研发、生产与销售。公司的主要产品是冻干人用狂犬病疫苗（人二倍体细胞）、ACYW135群脑膜炎球菌多糖疫苗。","listedPrice":70.37},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"康华生物(300841)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供康华生物(300841)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"康华生物,300841,康华生物股票,康华生物股票老虎,康华生物股票老虎国际,康华生物行情,康华生物股票行情,康华生物股价,康华生物股市,康华生物股票价格,康华生物股票交易,康华生物股票购买,康华生物股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"康华生物(300841)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供康华生物(300841)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}